Ranbaxy Laboratories Limited

BOM:500359 ISIN:INE015A01028

May 26, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Ranbaxy Laboratories Limited Company Summary

Ranbaxy Laboratories Limited (RLL), along with its subsidiaries and associates operates as an integrated international pharmaceutical organization with businesses encompassing the entire value chain in the production, marketing and distribution of dosage forms and active pharmaceutical ingredients. It has manufacturing facilities in 11 countries, namely Brazil, China, India, Ireland, Japan, Malaysia, Nigeria, Romania, South Africa, the United States and Vietnam. Its major markets include the United States, India, Europe, Russia / CIS, Brazil and South Africa. The major products include, inter alia, Simvastatin, CoAmoxyclav, Amoxycillin, Ciprofloxacin, Isotretinon and Cephalexin. Its research and development activities are principally carried out at its facilities in Gurgaon, near New Delhi, India. RLL’s segments include Pharmaceuticals and Other businesses. In November 2008, Daiichi Sankyo Co., Ltd. completed the takeover of RLL by buying a 63.9% stake.

COMPANY DATA

	Principal Sector	Health & Pharm

	Principal Industry	Biotechnology

	Homepage	www.ranbaxy.com

Key Developments: Ranbaxy Laboratories Limited

	Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R DEC 7, 2011 11:27 - Article Views: 1,078 Asian Activities Report for December 7, 2011 includes: Great Wall Motors (HKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R; Chevalier International Holdings Limited (HKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan; Daiichi Sankyo Co., Ltd (TYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (BOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market.

	Asian Activities Report for September 1, 2011: CBD Energy (ASX:CBD) Signs Management Agreement with the AusChina Energy Joint Venture SEP 1, 2011 12:00 - Article Views: 1,552 Asian Activities Report for September 1, 2011 includes: CBD Energy (ASX:CBD) has signed an agreement to participate in the management of the AusChina Energy Joint Venture; TVN Corporation Pty Ltd (ASX:TVN) announced the results from its latest drilling on the Nuurst Project in Mongolia; Uran Limited (ASX:URA) has commenced commercial open pit mining activities at the Emmanuel Project in Zambia; Aviva Corporation Limited (ASX:AVA) has recently completed a maiden resource estimate on the Bumbo Base Metal Deposit in West Kenya; Manas Resources Limited (ASX:MSR) has completed a 12,500 metre drilling program at Shambesai Gold Project in the Kyrgyz Republic; Daiichi Sankyo Company, Limited (TYO:4568) and Ranbaxy Laboratories Limited (BOM:500359) today announced a joint initiative to sponsor mobile healthcare clinics in India, Cameroon and Tanzania.

	Asian Markets Overview of December 9 DEC 9, 2009 13:30 - Article Views: 6,421 US stocks fell on Tuesday on disappointing corporate news and renewed worries over global credit markets. Asian stocks mostly opened lower today with Australian and Japanese markets slashed sharply at opening.

	Australian Market Report of January 22: Helped by Short Selling Ban JAN 22, 2009 13:00 - Article Views: 8,698 Yesterday the Australian stock market ended the day lower, led by financial stocks, on renewed worries about banking industry worldwide. The benchmark S&P/ASX200 index was down 1%, or 33.8 points, at 3442.8, while the broader All Ordinaries index was lower by 0.9%, or 30.2 points, at 3394.8. Regulator ASIC's move to extend a ban on covered short-selling of financial securities would give a positive lead to the banking industry.